May 30, 2024 - May 28th is The International Day of Action for Women’s Healthcare to raise awareness for diseases and conditions that affect women’s physical and emotional health. The Journal of Medicinal Chemistry published a special Collection and showcased 17 articles that address the ongoing research dedicated to the unmet medical needs in women’s healthcare. TenNor’s article “Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens” was chosen for inclusion in the Collection and recognized in advancing research in women’s healthcare.

Rifasutenizol (TNP-2198) is a novel dual-acting drug candidate currently under clinical development by TenNor Therapeutics for the treatment of microaerophilic and anaerobic bacterial infections, including H. pylori infection, bacterial vaginosis, and C. difficile infection.

Bacterial vaginosis (BV) is the most common vaginal problem for women, with an estimated prevalence of 30 ~ 50%. It is caused by an overgrowth of harmful, predominantly anaerobic, bacteria in the vagina, and the resultant imbalance between ‘good’ and ‘bad’ bacteria. As antibiotic resistance becomes increasingly problematic, the effectiveness of antimicrobial treatments for BV is declining, resulting in higher recurrence rates and a significant unmet clinical need. Rifasutenizol, with its unique multi-targeting synergistic mechanism, shows potential advantages in the treatment of BV by overcoming resistance and preventing recurrence.

Collection Link: https://pubs.acs.org/page/jmcmar/vi/womens-health?ref=feature.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com